Drug Abuse
In: Alcohol and Drug Abuse Ser
Intro -- Contents -- Preface -- Chapter 1 -- Opioid Treatment Programs and Related Federal Regulations( -- Summary -- Medication-Assisted Treatment (MAT) -- Methadone -- Buprenorphine -- Naltrexone -- Regulatory Framework -- Federal Food, Drug, and Cosmetic Act (FFDCA) -- Controlled Substances Act (CSA) -- Opioid Treatment Programs (OTPs) -- OTP Accreditation -- OTP Certification -- OTP Registration -- DATA-Waived Providers (DWPs) -- Practitioner Requirements -- Medication Requirements -- Chapter 2 -- Increase in Illicit Fentanyl Overdose Deaths* -- Summary -- What Is Fentanyl? -- Rise of Fentanyl Overdoses -- Availability of Fentanyl -- Policy Considerations -- Chapter 3 -- The Opioid Epidemic and the Food and Drug Administration: Legal Authorities and Recent Agency Action( -- Summary -- FDA Approval of Prescription Drugs and the Challenges of Opioids -- FDA Authority and Recent Agency Action Related to the Opioid Epidemic -- Decreasing Exposure and Preventing New Addiction -- Supporting the Treatment of Those with Opioid Use Disorder -- Fostering the Development of Novel Pain Treatment Therapies -- Improving Enforcement and Assessing Benefit Risk -- Selected Opioid-Related Bills in the 115th Congress That Would Amend the FD&C Act -- Chapter 4 -- High Intensity Drug Trafficking Areas (HIDTA) Program( -- Summary -- HIDTA Designations -- Coordination -- Funding -- HIDTA Issues for Consideration -- Unit of Inclusion -- County-Level Drug Trafficking Data -- Criteria for Inclusion -- Program Effectiveness -- Program Scope -- Use of Funds for Treatment and Prevention Initiatives -- Heroin Response Strategy -- HIDTA as an ONDCP Component -- Chapter 5 -- Legal Authorities Under the Controlled Substances Act to Combat the Opioid Crisis( -- Summary -- Brief Background on the Opioid Epidemic -- Overview of the CSA